vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Strategy Inc (MSTR). Click either name above to swap in a different company.

Strategy Inc is the larger business by last-quarter revenue ($123.0M vs $85.1M, roughly 1.4× 4D Molecular Therapeutics, Inc.). On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 1.9%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 3.3%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

Strategy Inc., formerly known as MicroStrategy, is an American company that provides business intelligence (BI) and mobile software. Founded in 1989 by Michael J. Saylor, Sanju Bansal, and Thomas Spahr, the firm develops software to analyze internal and external data in order to make business decisions and to develop mobile apps. It is a public company headquartered in Tysons Corner, Virginia, in the Washington metropolitan area. Its primary business analytics competitors include SAP SE Busin...

FDMT vs MSTR — Head-to-Head

Bigger by revenue
MSTR
MSTR
1.4× larger
MSTR
$123.0M
$85.1M
FDMT
Growing faster (revenue YoY)
FDMT
FDMT
+8508898.1% gap
FDMT
8508900.0%
1.9%
MSTR
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
3.3%
MSTR

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
FDMT
FDMT
MSTR
MSTR
Revenue
$85.1M
$123.0M
Net Profit
$19.4M
Gross Margin
66.1%
Operating Margin
17.3%
Net Margin
22.8%
Revenue YoY
8508900.0%
1.9%
Net Profit YoY
139.1%
EPS (diluted)
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
MSTR
MSTR
Q4 25
$85.1M
$123.0M
Q3 25
$90.0K
$128.7M
Q2 25
$15.0K
$114.5M
Q1 25
$14.0K
$111.1M
Q4 24
$1.0K
$120.7M
Q3 24
$3.0K
$116.1M
Q2 24
$5.0K
$111.4M
Q1 24
$28.0K
$115.2M
Net Profit
FDMT
FDMT
MSTR
MSTR
Q4 25
$19.4M
Q3 25
$-56.9M
$2.8B
Q2 25
$-54.7M
$10.0B
Q1 25
$-48.0M
$-4.2B
Q4 24
$-670.8M
Q3 24
$-43.8M
$-340.2M
Q2 24
$-35.0M
$-102.6M
Q1 24
$-32.4M
$-53.1M
Gross Margin
FDMT
FDMT
MSTR
MSTR
Q4 25
66.1%
Q3 25
70.5%
Q2 25
68.8%
Q1 25
69.4%
Q4 24
71.7%
Q3 24
70.4%
Q2 24
72.2%
Q1 24
74.0%
Operating Margin
FDMT
FDMT
MSTR
MSTR
Q4 25
17.3%
Q3 25
-67983.3%
Q2 25
-396373.3%
Q1 25
-383007.1%
-5331.4%
Q4 24
-842.1%
Q3 24
-1704400.0%
-372.7%
Q2 24
-849120.0%
-179.7%
Q1 24
-136200.0%
-176.8%
Net Margin
FDMT
FDMT
MSTR
MSTR
Q4 25
22.8%
Q3 25
-63195.6%
2164.1%
Q2 25
-364386.7%
8752.7%
Q1 25
-342657.1%
-3797.2%
Q4 24
-555.8%
Q3 24
-1461433.3%
-293.1%
Q2 24
-699060.0%
-92.0%
Q1 24
-115717.9%
-46.1%
EPS (diluted)
FDMT
FDMT
MSTR
MSTR
Q4 25
$0.43
Q3 25
$-1.01
$8.42
Q2 25
$-0.98
$32.60
Q1 25
$-0.86
$-16.49
Q4 24
$4.49
Q3 24
$-0.79
$-1.72
Q2 24
$-0.63
$-0.57
Q1 24
$-0.66
$-0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
MSTR
MSTR
Cash + ST InvestmentsLiquidity on hand
$402.7M
$2.3B
Total DebtLower is stronger
$8.2B
Stockholders' EquityBook value
$505.7M
$44.1B
Total Assets
$566.7M
$61.6B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
MSTR
MSTR
Q4 25
$402.7M
$2.3B
Q3 25
$305.1M
$54.3M
Q2 25
$293.2M
$50.1M
Q1 25
$321.4M
$60.3M
Q4 24
$424.9M
$38.1M
Q3 24
$501.9M
$46.3M
Q2 24
$541.9M
$66.9M
Q1 24
$525.9M
$81.3M
Total Debt
FDMT
FDMT
MSTR
MSTR
Q4 25
$8.2B
Q3 25
$8.2B
Q2 25
$8.2B
Q1 25
$8.1B
Q4 24
$7.2B
Q3 24
$4.2B
Q2 24
$3.8B
Q1 24
$3.6B
Stockholders' Equity
FDMT
FDMT
MSTR
MSTR
Q4 25
$505.7M
$44.1B
Q3 25
$369.0M
$52.3B
Q2 25
$420.9M
$47.5B
Q1 25
$469.7M
$32.2B
Q4 24
$510.6M
$18.2B
Q3 24
$552.9M
$3.8B
Q2 24
$588.3M
$2.8B
Q1 24
$600.6M
$2.4B
Total Assets
FDMT
FDMT
MSTR
MSTR
Q4 25
$566.7M
$61.6B
Q3 25
$424.0M
$73.6B
Q2 25
$473.6M
$64.8B
Q1 25
$515.7M
$43.9B
Q4 24
$560.4M
$25.8B
Q3 24
$604.0M
$8.3B
Q2 24
$620.1M
$7.1B
Q1 24
$629.9M
$6.4B
Debt / Equity
FDMT
FDMT
MSTR
MSTR
Q4 25
0.19×
Q3 25
0.16×
Q2 25
0.17×
Q1 25
0.25×
Q4 24
0.39×
Q3 24
1.12×
Q2 24
1.36×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
MSTR
MSTR
Operating Cash FlowLast quarter
$28.6M
Free Cash FlowOCF − Capex
$28.5M
FCF MarginFCF / Revenue
33.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
MSTR
MSTR
Q4 25
$28.6M
Q3 25
$-46.5M
$-8.3M
Q2 25
$-43.4M
$-34.9M
Q1 25
$-47.8M
$-2.4M
Q4 24
$-134.6M
$-17.3M
Q3 24
$-29.4M
$-41.0M
Q2 24
$-30.2M
$-23.3M
Q1 24
$-29.1M
$28.6M
Free Cash Flow
FDMT
FDMT
MSTR
MSTR
Q4 25
$28.5M
Q3 25
$-46.6M
$-11.1M
Q2 25
$-43.4M
$-37.0M
Q1 25
$-48.4M
$-5.1M
Q4 24
$-138.4M
$-17.6M
Q3 24
$-31.2M
$-41.4M
Q2 24
$-30.6M
$-24.1M
Q1 24
$-29.8M
$27.0M
FCF Margin
FDMT
FDMT
MSTR
MSTR
Q4 25
33.5%
Q3 25
-51765.6%
-8.6%
Q2 25
-289620.0%
-32.3%
Q1 25
-345635.7%
-4.6%
Q4 24
-13837100.0%
-14.6%
Q3 24
-1038966.7%
-35.7%
Q2 24
-611840.0%
-21.6%
Q1 24
-106421.4%
23.5%
Capex Intensity
FDMT
FDMT
MSTR
MSTR
Q4 25
0.1%
Q3 25
101.1%
2.2%
Q2 25
440.0%
1.8%
Q1 25
4507.1%
2.5%
Q4 24
378600.0%
0.2%
Q3 24
59266.7%
0.4%
Q2 24
6980.0%
0.6%
Q1 24
2535.7%
1.3%
Cash Conversion
FDMT
FDMT
MSTR
MSTR
Q4 25
1.47×
Q3 25
-0.00×
Q2 25
-0.00×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons